The Yale School of Medicine study published in Neuron reveals that GABA-alpha-5 receptors can paradoxically enhance calcium influx and neural plasticity even while suppressing firing, based on two-photon microscopy in mouse brain slices and in vivo models. This lab-based experimental work, not an RCT and with unspecified sample sizes typical of early mechanistic neuroscience, carries no disclosed conflicts but remains preclinical. Prior coverage in MedicalXpress focused narrowly on therapeutic surprise without noting how this aligns with earlier findings on GABA's role in long-term potentiation, such as those in a 2018 Nature Neuroscience paper by the Higley lab itself showing similar receptor-specific effects in cortical circuits. It also overlooks connections to a 2022 Cell Reports observational study on alpha-5 positive allosteric modulators in rodent models of schizophrenia, where plasticity changes correlated with behavioral flexibility rather than mere sedation. What original reporting missed is the risk that broad GABAergic drugs like benzodiazepines may inadvertently drive maladaptive plasticity in vulnerable circuits, potentially explaining treatment resistance in depression. Synthesizing these, the dual function implies future therapies should selectively engage alpha-5 pathways to harness learning benefits while avoiding global inhibition side effects.